Rigel Pharmaceuticals (RIGL) Stock Forecast & Price Target

Rigel Pharmaceuticals is supported by a strengthening commercial base, with total revenue guidance narrowed to $290M-$295M, ~$99M in cash and equivalents, and expectations to report positive net income for the full year while funding existing and new clinical programs. The first partial quarter for VEPPANU is encouraging, as it generated $6.6M in net product sales from mid-August to quarter-end, shipped to 100+ patients/clinics, and showed good refill rates, while management cited an average peak penetration opportunity of 21% of 2L patients. Clinical momentum also remains a key driver, with R289 showing favorable signals in a very progressed population and Gavreto posting encouraging efficacy across RET fusion-positive tumors, including a 53% overall response rate in pooled solid tumors and an 81.3% rate in thyroid cancer.

Rigel Pharmaceuticals is viewed negatively because its core growth driver remains highly exposed to clinical failure, highlighted by the missed primary endpoint in the pivotal warm AIHA trial for fostamatinib, which raises the risk of weak efficacy data and delayed or denied approval. The company also faces heavy regulatory scrutiny from the FDA and international agencies, where any concerns about safety, efficacy, or manufacturability could force additional studies and slow commercialization. Even with approved products, commercialization is challenged by intense competition in ITP and physician inertia, which could limit adoption and undermine the market potential of its pipeline and partnered assets.